GB Sciences Signs Letter of Intent for a License to Develop and Market Their Cannabinoid-Based Parkinson's Formulation With Endopure Life Sciences

By: Investing.com

Jul 23 2024
6
324 Views

GB Sciences Signs Letter of Intent for a License to Develop and Market Their Cannabinoid-Based Parkinson's Formulation With Endopure Life Sciences

GB Sciences' Licensing Deal with Endopure Life Sciences will also include Rights to Develop and Market GB Sciences' Cannabinoid-based Treatments for a Suite of Neurological Disorders
LAS VEGAS, NV /… [+6020 chars]

Cosmos Health Signs Distribution Agreement with ZENDON s.r.o. in Slovakia, Hungary, Poland, and Czechia for Its Sky Premium Life Nutraceutical Products; Gains Access to More than 6,000 Stores of Leadi

GB Sciences Signs Letter of Intent for a License to Develop and Market Their Cannabinoid-Based Parkinson's Formulation With Endopure Life Sciences

Weekly Climate and Energy News Roundup #603

Gut Feeling Off This Monsoon? This Humble Moong Water Recipe Is Your Answer

As monsoon sets in, respiratory, malaria drugs see demand rise

Zoetis Foundation and Zoetis Deepen Commitment to Global Disaster Relief with American Red Cross and American Humane

Tapping social media and AI to speed supply chain assistance during disasters

UN urges Gilead to 'make history' with game-changing HIV drug

Monte Rosa Therapeutics (NASDAQ:GLUE) Rating Reiterated by Piper Sandler

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Up 29.3% in June

Arrowhead reports promising obesity treatment data

Ottawa announces $89M for 10 conservation projects

Share this page

Guest Posts by Easy Branches

anchor links ads by Easy Branches

Get Reliable Matka Guessing Forum with our Satta Matka Expert and Get all Matka Chart For Free.

GB Sciences Signs Letter of Intent for a License to Develop and Market Their Cannabinoid-Based Parkinson's Formulation With Endopure Life Sciences

Related